KYXATA - (20MG/2ML, 80MG/8ML, 500MG/50ML ; Solution)

Generic Name	CARBOPLATIN	**Innovator**	AVYXA HOLDINGS
Dosage	20MG/2ML, 80MG/8ML, 500MG/50ML ; Solution	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	None	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	KYXATA is a platinum-based drug indicated in adults: • As part of a combination regimen, for the initial treatment of advanced ovarian carcinoma. • As a single-agent for the treatment of ovarian carcinoma recurrent after prior chemotherapy.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.